Keith R Hornberger

This inventor holds 19 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Protein Degradation. Top assignees: Arvinas Operations, Inc., Yale University, Boehringer Ingelheim International Gmbh. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keith R Hornberger. Retrieved from https://idiyas.com/inventor/keith-r-hornberger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 18)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 34(Granted Patents)

Company Filing History:

17 out of 67

Arvinas Operations, Inc.

Boehringer Ingelheim International Gmbh

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Proteolysis

Cereblon Ligands

Estrogen Receptor

Fibrosarcoma

Androgen Receptor

Tetrahydronaphthalene

Aldosterone Synthase

Bifunctional Compounds

Targeted Degradation

Compounds

Methods

Polypeptides

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12552783 - Modulators of proteolysis and associated methods of use (2026-02-17),

2. 12441708 - Cereblon ligands and bifunctional compounds comprising the same (2025-10-14),

3. 12275716 - Modulators of estrogen receptor proteolysis and associated methods of use (2025-04-14),

4. 12239711 - Cereblon ligands and bifunctional compounds comprising the same (2025-03-04),

5. 12180193 - Accelerating fibrosarcoma protein degrading compounds and associated methods of use (2024-12-31),

6. 12172981 - Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders (2024-12-24),

7. 12156916 - Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use (2024-12-03),

8. 12077509 - Compounds and methods for the targeted degradation of androgen receptor (2024-09-03),

9. 11986531 - Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides (2024-05-21),

10. 11964945 - Compounds and methods for the targeted degradation of androgen receptor (2024-04-23),

11. 11957759 - Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use (2024-04-16),

12. 11173211 - Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides (2021-11-16),

13. 11161841 - Modulators of proteolysis and associated methods of use (2021-11-02),

14. 11104666 - Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders (2021-08-31),

15. 10806737 - Compounds and methods for the targeted degradation of fetal liver kinase polypeptides (2020-10-20),

Title: Keith R. Hornberger: Innovator in Estrogen Receptor Modulation

Introduction

Keith R. Hornberger is a prominent inventor based in Southbury, CT, known for his significant contributions to biomedical research and drug development. With a total of 17 patents to his name, his work primarily focuses on innovative compounds and methods that have the potential to tackle various diseases associated with target protein accumulation.

Latest Patents

Hornberger's latest patents include groundbreaking developments in the field of estrogen receptor modulation. One of his notable patents is for bifunctional compounds that act as modulators of estrogen receptor proteolysis. These compounds feature a unique structure that allows a ligase-binding moiety to bind to the target protein, utilizing the action of ubiquitin ligases to effect degradation and inhibition of the target protein. This mechanism exhibits a wide range of pharmacological activities and holds promise for treating diseases caused by the aggregation of harmful proteins.

Another significant patent explores cereblon E3 ligase binding compounds, again emphasizing the utility of bifunctional compounds. These compounds are designed to promote targeted ubiquitination and inhibit various polypeptides and proteins, showcasing an impressive range of pharmacological activities in the process.

Career Highlights

Throughout his career, Keith R. Hornberger has worked with prominent organizations including Arvinas Operations, Inc. and Yale University. His work in these institutions has contributed to a solid understanding of protein modulation and its applications in therapeutic settings, marking him as a valuable asset in the field of pharmaceutical innovation.

Collaborations

Hornberger has collaborated with a number of talented colleagues, notably Andrew Philip Crew and Jing Wang. These collaborations have fostered an environment of innovation, allowing for the exchange of ideas and advancements in biomedical research.

Conclusion

In summary, Keith R. Hornberger's innovative work in the realm of estrogen receptor modulation through bifunctional compounds positions him as a leading inventor in his field. His patents reflect a commitment to addressing complex medical challenges and enhancing our understanding of protein dynamics in therapeutic contexts. His ongoing contributions will undoubtedly pave the way for future advancements in drug development and disease treatment.

Profile summary based on public USPTO records.